IL17A and breast carcinoma: To this end, we developed HDN-TIMP2,V3: a novel bi-specific heterodimer that successfully inhibits both MMP-9 activation and IL-17A-induced cytokine secretion to synergistically inhibit the invasion of breast cancer cells.